199 related articles for article (PubMed ID: 38476327)
1. Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Chen Q; Wei G; Wang Y; Li X; Zhao Q; Zhu L; Xiao Q; Xiong X
Front Pharmacol; 2024; 15():1338044. PubMed ID: 38476327
[No Abstract] [Full Text] [Related]
2. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.
Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B
Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348
[TBL] [Abstract][Full Text] [Related]
3. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.
Jiang X; Zhang Z; Li C; Zhang S; Su Q; Yang S; Liu X; Hu Y; Pu X
Front Pharmacol; 2022; 13():896947. PubMed ID: 35784710
[No Abstract] [Full Text] [Related]
5. Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists.
Xu X; Feng J; Cui Y; Li P; Dong J; Liao L
J Diabetes; 2024 Jun; 16(6):e13566. PubMed ID: 38753662
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis.
Chen Q; Liang Y; Yan J; Du Y; Li M; Chen Z; Zhou J
Diabetes Res Clin Pract; 2023 Jan; 195():110210. PubMed ID: 36509181
[TBL] [Abstract][Full Text] [Related]
8. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
Zheng Y; Ma S; Huang Q; Fang Y; Tan H; Chen Y; Li C
Kidney Blood Press Res; 2022; 47(4):219-228. PubMed ID: 35034019
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Zhang MZ; Bao W; Zheng QY; Wang YH; Sun LY
Front Pharmacol; 2022; 13():819327. PubMed ID: 35197856
[No Abstract] [Full Text] [Related]
15. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Alexandrou ME; Papagianni A; Tsapas A; Loutradis C; Boutou A; Piperidou A; Papadopoulou D; Ruilope L; Bakris G; Sarafidis P
J Hypertens; 2019 Dec; 37(12):2307-2324. PubMed ID: 31688290
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
17. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
[TBL] [Abstract][Full Text] [Related]
18. The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.
Provenzano M; Jongs N; Vart P; Stefánsson BV; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL;
Kidney Int Rep; 2022 Mar; 7(3):436-443. PubMed ID: 35257056
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials.
Xu Y; Qiu Z; Yang R; Wu Y; Cheng X
Medicine (Baltimore); 2018 Dec; 97(51):e13690. PubMed ID: 30572494
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
